Potential $285M: Ipsen and Active Biotech in TASQ Deal
By Cormac Sheridan
Tuesday, April 19, 2011
Active Biotech AB is banking an up-front payment of $35.6 million and could get $249.4 million more on the back of a partnering deal with Ipsen SA on its Phase III cancer drug tasquinimod (TASQ).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.